TACS: POC - Transfusion Algorithm Cardiac Study

Sponsor
University Health Network, Toronto (Other)
Overall Status
Completed
CT.gov ID
NCT02200419
Collaborator
(none)
7,402
12
1
23
616.8
26.8

Study Details

Study Description

Brief Summary

This multi-centre study will provide sound, generalizable data on the effectiveness of a POC-based algorithm to determine to what extent this guideline can reduce blood product transfusions. Investigators will study outcomes in 7000 patients undergoing heart surgery at 10 participating hospitals. The proposed trial addresses several important research and clinical issues and has the potential to markedly improve the transfusion management and surgical care in general of cardiac surgery patients.

The intervention will be a novel POC-based algorithm that has been shown in a pilot study by us to be associated with a substantial reduction in blood product transfusions. The algorithm will employ viscoelastic and aggregometric POC-tests and an objective measure of blood loss. The primary outcome will be avoidance of red blood cell transfusion during hospitalization. The study has a 90% power to detect a 12% increase in avoidance rate. Secondary outcomes will include avoidance of red blood cell use and other blood products (plasma, platelets, and cryoprecipitate), units of blood products transfused, and adverse clinical outcomes related to transfusion (acute kidney injury, infections, and death). Data will also be collected for future health-economics analyses.

Largely due to the limitations of existing evidence, however, such algorithms are rarely used in clinical practice. The proposed trial will provide sound, generalizable data on the effectiveness of a POC-based algorithm to guide their future use. An integrated blood management algorithm that employs POC coagulation tests will reduce blood product transfusions in cardiac surgery, thereby improving clinical outcomes.

Does an integrated blood transfusion algorithm that employs POC coagulation tests applied across a network of hospitals reduce blood transfusions and associated adverse outcomes in cardiac surgery?

Condition or Disease Intervention/Treatment Phase
  • Other: POC-based transfusion algorithm
N/A

Detailed Description

Despite major advances in cardiac surgery, coagulopathy continues to carry a heavy burden in cases that require the use of cardiopulmonary bypass (CPB), occurring frequently and resulting in excessive blood loss, blood product transfusions, and adverse clinical outcomes. Current management of coagulopathy is hampered by the inability of conventional laboratory tests to delineate its etiology in a timely manner, thereby precluding timely and targeted transfusion therapy. With the advent of point-of-care (POC) coagulation tests that can rapidly identify the etiology of coagulopathy, it may now be possible to reduce the burden of coagulopathy and thereby reduce transfusions and adverse outcomes. Several single-centre studies (including one by the investigator group) have found that the use of POC-based algorithms in cardiac surgery can markedly reduce blood product transfusions and by that means reduce morbidities and mortality.

Study Design

Study Type:
Interventional
Actual Enrollment :
7402 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Blood Conservation in Cardiac Surgery Using a Novel Transfusion Algorithm Based on Point-of-care Testing-A Stepped-wedge Cluster Randomized Controlled Trial
Study Start Date :
Oct 1, 2014
Actual Primary Completion Date :
Sep 1, 2016
Actual Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Other: Transfusion Algorithm

Hospitals will be randomized to the intervention arm of the study in a stratified manner.

Other: POC-based transfusion algorithm
A transfusion algorithm based on point-of-care coagulation testing.

Outcome Measures

Primary Outcome Measures

  1. Point Of Care (POC) Transfusion Algorithm Cardiac Study [2.5 years]

    The primary outcome measure will be the proportion of patients who receive any allogeneic red blood cell (RBC) transfusion from admission before surgery to end of follow-up.

Secondary Outcome Measures

  1. Transfusion [7 days]

    Allogeneic blood products (platelets, plasma, cryoprecipitate) or coagulation factors (e.g., fibrinogen concentrate, factor VIIa), or undergo re-exploration; units of blood products transfused, nadir hemoglobin concentration (to identify changes in transfusion practice that may be unrelated to treatment of coagulopathy)

  2. Blood loss [24 hours]

    Chest-tube drainage at 6 and 24 hours after surgery

  3. Ventilation and hospital stay [24 hours to 7 days]

    Duration of mechanical ventilation and length of stay in the ICU and hospital

  4. Kidney injury [48 hours]

    Incidence of acute kidney injury, defined as a ≥ 2-fold in increase in creatinine or new renal replacement therapy within 48 hours after surgery

  5. Post operative complications [7 days]

    Arrhythmias, sternal infection, myocardial infarction, stroke, thromboembolic events, and death

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Hospital Inclusion:
  • Participating hospitals must not currently be using a POC-based blood conservation algorithm; must have an in-hospital RBC transfusion rate of > 35% and platelet or plasma transfusion rates of > 20%; must conduct > 600 cardiac surgeries employing CPB per year; and must have commitments from departments of Anesthesia, Cardiac Surgery, and Laboratory Medicine to support the study and to abide by the algorithm

  • Blood transfusion algorithm instituted as standard-of-care at participating hospitals

  • All adult (≥ 18 years) patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) will be included in the analysis.

Exclusion Criteria: Hospitals not meeting inclusion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dr. Charles McAdams Calgary Alberta Canada T2N 2T9
2 Blaine Achen Edmonton Alberta Canada
3 Dr. Terry Waters Vancouver British Columbia Canada V5Z 1M9
4 Dr. Sukhpal Brar Vancouver British Columbia Canada
5 Dr. H. Grocott Winnipeg Manitoba Canada R2H 2A6
6 Dr. Summer Syed Hamilton Ontario Canada L8N 3Z5
7 Dr. Christopher Harle London Ontario Canada N6A 5A5
8 Dr. Daniel Kim Newmarket Ontario Canada L3Y 2P9
9 Dr. D. Tran Ottawa Ontario Canada K1Y 4W7
10 Dr. F. Moussa Toronto Ontario Canada M4N 3M5
11 Dr. E. Medicis Fleurimont Quebec Canada J1H 5N4
12 Dr. J. Bussieres Sainte -Foy Quebec Canada G1V 4G5

Sponsors and Collaborators

  • University Health Network, Toronto

Investigators

  • Principal Investigator: Keyvan Karkouti, MD, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jo Carroll, Research Manager, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT02200419
Other Study ID Numbers:
  • 14-7495-A
First Posted:
Jul 25, 2014
Last Update Posted:
Dec 5, 2016
Last Verified:
Dec 1, 2016
Keywords provided by Jo Carroll, Research Manager, University Health Network, Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 5, 2016